|
|
Article: ECRI Assessment Concludes Drug-Eluting Stents Improve Outcomes in Heart Stent Procedures.
- Article from:
- PR Newswire
- Article date:
- September 10, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PLYMOUTH MEETING, Pa., Sept. 10 /PRNewswire/ -- ECRI's technology assessment of published studies on the implantation of drug-eluting stents after angioplasty concluded that the rate of coronary artery restenosis (reblockage or renarrowing of the stented artery) was as much as 64 times lower than that of bare-metal stents. The studies included in ECRI's analysis compared the effectiveness of drug-eluting stents, which are coated with either paclitaxel, a drug that inhibits cell growth, or sirolimus, an anti-inflammatory agent, to bare-metal (uncoated) stents. One sirolimus-eluting stent, manufactured by Cordis Corporation, a subsidiary of Johnson & Johnson, received FDA ...